Therapy of clinical stage IIA and IIB seminoma: a systematic review - Takeaways - MDSpire

Therapy of clinical stage IIA and IIB seminoma: a systematic review

  • By

  • Julia Heinzelbecker

  • Stefanie Schmidt

  • Julia Lackner

  • Jonas Busch

  • Carsten Bokemeyer

  • Johannes Classen

  • Annette Dieing

  • Oliver Hakenberg

  • Susanne Krege

  • Alexandros Papachristofilou

  • David Pfister

  • Christian Ruf

  • Hans Schmelz

  • Heinz Schmidberger

  • Rainer Souchon

  • Christian Winter

  • Friedemann Zengerling

  • Sabine Kliesch

  • Peter Albers

  • Christoph Oing

  • November 15, 2021

  • 0 min

Share

  • 1

    Clinical stage IIA/B seminoma is a rare form of testicular cancer, accounting for only 7% of all testicular cancer cases.

  • 2

    Established guidelines recommend radiotherapy or chemotherapy for treating CS IIA/B seminoma, but optimal treatment evidence is limited.

  • 3

    Survival rates for CS IIA/B seminoma patients approach 100%, making treatment-related toxicities a significant concern.

  • 4

    The systematic review included seven studies with 5049 patients, comparing outcomes of radiotherapy and chemotherapy.

  • 5

    Radiotherapy showed lower relapse rates and better overall survival compared to chemotherapy in CS IIA/B seminoma patients.

Original Source(s)

Therapy of clinical stage IIA and IIB seminoma: a systematic review

  • by Julia Heinzelbecker, Stefanie Schmidt, Julia Lackner, Jonas Busch, Carsten Bokemeyer, Johannes Classen, Annette Dieing, Oliver Hakenberg, Susanne Krege, Alexandros Papachristofilou, David Pfister, Christian Ruf, Hans Schmelz, Heinz Schmidberger, Rainer Souchon, Christian Winter, Friedemann Zengerling, Sabine Kliesch, Peter Albers, Christoph Oing

  • November 15, 2021

Related Content

Innovative Roswell Park Radiation Therapy Protocol in Lung Cancer to Be Highlighted at ASTRO Annual Meeting

Experts from Roswell Park Comprehensive Cancer Center will share the findings of a novel approach using radiation therapy to treat lung cancer at the American Society for Radiation Oncology (ASTRO) Annual Meeting Sept. 27-Oct. 1, 2025, in San Francisco.

  • by

  • September 23, 2025

  • 3 min
A volume-controlled, anatomy-driven autoplanning strategy for whole-pelvic volumetric modulated arc therapy

Dana-Farber Research News 03.15.2026

This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from February 16 - 28.

  • by

  • March 15, 2026

  • 21 min